Cargando…
Intravascular Stem Cell Bioreactor for Prevention of Adverse Remodeling After Myocardial Infarction
BACKGROUND: Prevention of adverse remodeling after myocardial infarction (MI) is an important goal of stem cell therapy. Clinical trial results vary, however, and poor cell retention and survival after delivery likely limit the opportunity to exert beneficial effects. To overcome these limitations,...
Autores principales: | Johnston, Peter V., Hwang, Chao‐Wei, Bogdan, Virginia, Mills, Kevin J., Eggan, Elliott R., Leszczynska, Aleksandra, Wu, Katherine C., Herzka, Daniel A., Brinker, Jeffrey A., Schulman, Steven P., Banerjee, Monisha, Florea, Victoria, Natsumeda, Makoto, Tompkins, Bryon, Balkan, Wayne, Hare, Joshua M., Tomaselli, Gordon F., Weiss, Robert G., Gerstenblith, Gary |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6761667/ https://www.ncbi.nlm.nih.gov/pubmed/31340693 http://dx.doi.org/10.1161/JAHA.119.012351 |
Ejemplares similares
-
Comparison of Mesenchymal Stem Cell Efficacy in Ischemic Versus Nonischemic Dilated Cardiomyopathy
por: Tompkins, Bryon A., et al.
Publicado: (2018) -
Perspectives on the Evolution of Stem Cell Therapy for Heart Failure
por: Tompkins, Bryon, et al.
Publicado: (2015) -
Allogeneic Cell Combination Therapy Ameliorates Chronic Kidney Disease-Induced Heart Failure with Preserved Ejection Fraction
por: Rieger, Angela C, et al.
Publicado: (2022) -
Mesenchymal Stem Cell Therapy for Aging Frailty
por: Schulman, Ivonne Hernandez, et al.
Publicado: (2018) -
Genetic determinants of responsiveness to mesenchymal stem cell injections in non-ischemic dilated cardiomyopathy
por: Rieger, Angela C., et al.
Publicado: (2019)